Serambeque Beatriz, Mestre Catarina, Hundarova Kristina, Marto Carlos Miguel, Oliveiros Bárbara, Gomes Ana Rita, Teixo Ricardo, Carvalho Ana Sofia, Botelho Maria Filomena, Matthiesen Rune, Carvalho Maria João, Laranjo Mafalda
Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, 3000-548 Coimbra, Portugal.
Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), 3000-548 Coimbra, Portugal.
Biology (Basel). 2024 Aug 1;13(8):584. doi: 10.3390/biology13080584.
Proteomics can be a robust tool in protein identification and regulation, allowing the discovery of potential biomarkers. In clinical practice, the management of endometrial cancer can be challenging. Thus, identifying promising markers could be beneficial, helping both in diagnosis and prognostic stratification, even predicting the response to therapy. Therefore, this manuscript systematically reviews the existing evidence of the proteomic profile of human endometrial cancer. The literature search was conducted via Medline (through PubMed) and the Web of Science. The inclusion criteria were clinical, in vitro, and in vivo original studies reporting proteomic analysis using all types of samples to map the human endometrial cancer proteome. A total of 55 publications were included in this review. Most of the articles carried out a proteomic analysis on endometrial tissue, serum and plasma samples, which enabled the identification of several potential diagnostic and prognostic biomarkers. In addition, eight articles were analyzed regarding the identified proteins, where three studies showed a strong correlation, sharing forty-five proteins. This analysis also allowed the identification of the 10 most frequently reported proteins in these studies: EGFR, PGRMC1, CSE1L, MYDGF, STMN1, CASP3 ANXA2, YBX1, ANXA1, and MYH11. Proteomics-based approaches pointed out potential diagnostic and prognostic candidates for endometrial cancer. However, there is a lack of studies exploring novel therapeutic targets.
蛋白质组学可以成为蛋白质鉴定和调控方面的强大工具，有助于发现潜在的生物标志物。在临床实践中，子宫内膜癌的管理颇具挑战性。因此，识别有前景的标志物可能有益，有助于诊断和预后分层，甚至能预测对治疗的反应。因此，本手稿系统回顾了人类子宫内膜癌蛋白质组学概况的现有证据。通过Medline（经由PubMed）和科学网进行文献检索。纳入标准为临床、体外和体内的原始研究，这些研究报告了使用各类样本进行蛋白质组学分析以绘制人类子宫内膜癌蛋白质组图谱。本综述共纳入55篇出版物。大多数文章对子宫内膜组织、血清和血浆样本进行了蛋白质组学分析，从而能够识别出几种潜在的诊断和预后生物标志物。此外，对八篇关于已鉴定蛋白质的文章进行了分析，其中三项研究显示出强相关性，共有45种蛋白质相同。该分析还确定了这些研究中最常报告的10种蛋白质：表皮生长因子受体（EGFR）、孕酮受体膜组分1（PGRMC1）、染色体分离维持蛋白1（CSE1L）、肌细胞衍生生长因子（MYDGF）、微管相关蛋白2（STMN1）、半胱天冬酶3（CASP3）、膜联蛋白A2（ANXA2）、Y盒结合蛋白1（YBX1）、膜联蛋白A1（ANXA1）和肌球蛋白重链11（MYH11）。基于蛋白质组学的方法指出了子宫内膜癌潜在的诊断和预后候选标志物。然而，缺乏探索新型治疗靶点的研究。
